Filing Flows › BioNexus Gene Lab (BGLC) › Q2 2025
BioNexus Gene Lab (BGLC) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 18, 2025
BioNexus Gene Lab (BGLC) reported revenue of $2.3M for the second quarter 2025 (Q2 2025), +14% from a year earlier and +6% from the quarter before. Operating margin was -27.0%, net loss $616K (27.3% of revenue).
BioNexus Gene Lab, Q2 2025: revenue $2.3M (+14% year over year), operating margin -27.0%, net loss $616K, operating cash flow −$738K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.3M | +6% | +14% |
| Operating profit | −$611K | — | — |
| Net earnings | −$616K | — | — |
| Operating cash flow | −$738K | — | — |
What changed
Revenue was $2.3M in Q2 2025, up 14% year over year and up 6% from the previous quarter.
Gross margin was 16.3%, up 1.7 points from a year earlier. Operating costs exceeded revenue by $611K, an operating margin of -27.0%. Operating expenses grew 3214% against revenue growth of 14%. The quarter ended with a net loss of $616K, narrower than the previous quarter's $623K loss.
Operating cash flow was −$738K. Non-cash charges added back $28K of depreciation. Working capital and other items used $150K. Capital expenditures of $21K exceeded it, leaving free cash flow of −$759K.
Questions
What was BioNexus Gene Lab's revenue in the second quarter 2025?
BioNexus Gene Lab (BGLC) reported revenue of $2.3M for the second quarter 2025 (Q2 2025), +14% from a year earlier and +6% from the quarter before.
Was BioNexus Gene Lab profitable in the second quarter 2025?
Operating loss was $611K (-27.0% of revenue) and net loss $616K.
Source: BioNexus Gene Lab 10-Q on SEC EDGAR.